approach in patients with subacute massive pulmonary embolism and our preliminary findings are reported here.
Subacute massive pulmonary embolism has been clearly defined by Sutton et al. I Patients have a history of progressive breathlessness of at least two weeks' duration, without an episode of cardiovascular collapse, and pulmonary angiography shows obstruction of at least half of the pulmonary circulation. Breathlessness is characteristically insidious in onset, chest pain and haemoptysis may or may not occur, and the findings on examination usually suggest right heart strain. Although it is an uncommon condition subacute massive pulmonary embolism has a high early mortality rate and the response to treatment with heparin or streptokinase may be disappointing.2 The reason for the poor response to treatment may lie in the age of the thrombus; the plasminogen content of established thrombus falls with time3 and plasminogen is the major substrate on which streptokinase acts to produce clot lysis. Improved lysis of old thrombus has been shown in peripheral veins by the infusion of plasminogen followed by streptokinase4 and in acute pulmonary embolism by the use of a combination of plasminogen and urokinase. 
Patients and methods
In five consecutive patients in whom the clinical features suggested subacute massive pulmonary embolism the diagnosis was confirmed by pulmonary angiography and pulmonary artery pressures were measured with standard electronic pressure transducers. Cardiac output was not measured. Angiograms were reported according to a numerical scoring system6 to define the extent to which blood vessels were affected (score 0-16) and regional blood flow was reduced (score 0-18). The scores for vascular involvement and flow were added. A score of 0 represents a normal pulmonary angiogram whereas a theoretical score of 34 would represent complete obstruction of pulmonary flow with all pulmonary arteries affected by clot. A score of 17 or greater (that is, > 50%) represents "massive" pulmonary embolism.
Each patient received human placental plasminogen (lys plasminogen) 150 PA-pulmonary artery.
immediately afterwards through the same catheter. A loading dose of 600 000 units in 100 ml 5% dextrose was followed by a continuous infusion of 100 000 units in 50 ml 5% dextrose hourly for 24 hours. A bolus of hydrocortisone 100 mg intravenously every six hours was given during the infusion to minimise reactions to streptokinase. Pulmonary artery pressure measurements and angiography were repeated at the end of the streptokinase infusion and a decision was made on the need for further thrombolytic treatment. In two patients the same sequence of plasminogen followed by streptokinase was repeated. Thereafter heparin was given by continuous infusion until the patient was fully mobile and this was followed by long term anticoagulation with warfarin.
Vessels affected (%) 
Discussion
Thrombolytic treatment in acute pulmonary embolism increases the rate of resolution more than heparin plus coumarin anticoagulants67 but the use of such thrombolytic therapy is usually reserved for patients with large emboli and haemodynamic disturbance. Subacute massive pulmonary embolism responds less well to streptokinase,2 possibly because the embolic material is relatively old and may therefore contain less plasminogen than recently formed thrombus.3
Two important but uncontrolled studies of thrombolytic therapy and plasminogen have shown improved lysis of thrombus. Kakkar and his colleagues4 treated 12 patients with established deep vein thrombosis (mean duration 8-1 days) with intermittent infusions of plasminogen followed by streptokinase over a period of five days and compared this group with a further five patients treated with streptokinase alone. Substantial lysis occurred in all those treated with plasminogen and streptokinase, lysis being complete in eight cases, whereas little or no lysis occurred in the patients treated with streptokinase alone. Griguer and colleagues' studied plasminogen and urokinase in acute pulmonary embolism and suggested that this regimen may be more effective than urokinase alone when embolism has occurred more than five days before treatment is begun or when urokinase alone has failed. The effectiveness of such regimens may in part be due to the use of human placental plasminogen (lys plasminogen), which binds more firmly to thrombus than the normal circulating form of plasminogen (glu plasminogen). 8 Our results in patients with subacute massive pulmonary embolism, in which some of the embolus in the pulmonary arteries may be at least a month old, confirm that plasminogen in conjunction with thrombolytic treatment is particularly effective in producing lysis of older pulmonary emboli. This finding is in keeping with the observations that old thrombus contains only small quantities of plasminogen and that administered lys plasminogen binds firmly to thrombus, rendering it more susceptible to lysis by streptokinase.
It is possible that in patient 5, who was later shown to have choriocarcinoma, some of the embolic material may have been tumour tissue. We think that this is unlikely in view of the very rapid resolution seen after plasminogen and streptokinase (fig 2) .
Although this study was uncontrolled we think that it is unlikely that such rapid clearance of longstanding thrombus would have occurred with streptokinase alone. In a previous study of 24 patients with subacute massive pulmonary embolism there were 9 (38%) early deaths, four in patients who had received at least 24 hours' treatment with streptokinase. Of a further eight patients treated with streptokinase for 72 hours, two showed no angiographic improvement.2 In contrast, all five of our patients showed considerable haemodynamic and clinical improvement after treatment with plasminogen and streptokinase.
We have studied only a small number of patients; these are our preliminary findings, and the study was not controlled. Nevertheless we believe that the Subacute massive pulmonary embolism treated with plasminogen and streptokinase results are important since subacute massive pulmonary embolism, although uncommon, has a high mortality rate when treated by conventional means. A controlled study of plasminogen with streptokinase and streptokinase alone is now being undertaken but will not be complete for several years because of the rarity of such patients.
We suggest that, while better evidence is awaited, the use of plasminogen and streptokinase in combination should be considered in patients with subacute massive pulmonary embolism who have considerable haemodynamic disturbance and have failed to respond to heparin or streptokinase alone. 
